Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshimasa Oyama

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Current Pharmaceutical Design|July 2, 2019
Dose-dependent Effects of Esmolol-epinephrine Combination Therapy in Myocardial Ischemia and Reperfusion InjuryYoshimasa Oyama, Justin Blaskowsky, Tobias Eckle
Chronobiology International|May 26, 2021
Targeting circadian PER2 as therapy in myocardial ischemia and reperfusion injuryYoshimasa Oyama, Lori A Walker, Tobias Eckle
Trends in Molecular Medicine|May 13, 2021
Circadian Angiopoietin-Like-4 as a Novel Therapy in Cardiovascular DiseaseSydney Shuff, Yoshimasa Oyama, Lori Walker, et al.
Current Pharmaceutical Design|April 16, 2020
A Role for the Adenosine ADORA2B Receptor in Midazolam Induced Cognitive DysfunctionJennifer Gile, Yoshimasa Oyama, Sydney Shuff, et al.
Current Pharmaceutical Design|July 13, 2017
Circadian MicroRNAs in CardioprotectionYoshimasa Oyama, Colleen Marie Bartman, Jennifer Gile, et al.
JA Clinical Reports|October 19, 2022
Long-term delayed emergence after remimazolam-based general anesthesia: a case reportTsubasa Takemori, Yoshimasa Oyama, Takenori Makino, et al.
Cureus|June 1, 2026
Laparoscopic Appendectomy for Acute Appendicitis With Adnexal Adhesion During the Third Trimester of Pregnancy: A Case ReportKazunori Masahata, Takeya Hara, Rikuto Hirose, et al.
Cureus|November 25, 2025
Association Between Postoperative Complications and Real-Time Oxidative Stress Measurements Using Electron Spin Resonance: An Observational StudyShigekiyo Matsumoto, Yoshihide Kuribayashi, Takenori Makino, et al.
Plos One|December 31, 2020
Intense light as anticoagulant therapy in humansYoshimasa Oyama, Sydney Shuff, Pavel Davizon-Castillo, et al.
Current Pharmaceutical Design|September 25, 2018
The Circadian PER2 Enhancer Nobiletin Reverses the Deleterious Effects of Midazolam in Myocardial Ischemia and Reperfusion InjuryYoshimasa Oyama, Colleen Marie Bartman, Jennifer Gile, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Current Pharmaceutical Design|July 2, 2019
Dose-dependent Effects of Esmolol-epinephrine Combination Therapy in Myocardial Ischemia and Reperfusion InjuryYoshimasa Oyama, Justin Blaskowsky, Tobias Eckle
Chronobiology International|May 26, 2021
Targeting circadian PER2 as therapy in myocardial ischemia and reperfusion injuryYoshimasa Oyama, Lori A Walker, Tobias Eckle
Trends in Molecular Medicine|May 13, 2021
Circadian Angiopoietin-Like-4 as a Novel Therapy in Cardiovascular DiseaseSydney Shuff, Yoshimasa Oyama, Lori Walker, et al.
Current Pharmaceutical Design|April 16, 2020
A Role for the Adenosine ADORA2B Receptor in Midazolam Induced Cognitive DysfunctionJennifer Gile, Yoshimasa Oyama, Sydney Shuff, et al.
Current Pharmaceutical Design|July 13, 2017
Circadian MicroRNAs in CardioprotectionYoshimasa Oyama, Colleen Marie Bartman, Jennifer Gile, et al.
JA Clinical Reports|October 19, 2022
Long-term delayed emergence after remimazolam-based general anesthesia: a case reportTsubasa Takemori, Yoshimasa Oyama, Takenori Makino, et al.
Cureus|June 1, 2026
Laparoscopic Appendectomy for Acute Appendicitis With Adnexal Adhesion During the Third Trimester of Pregnancy: A Case ReportKazunori Masahata, Takeya Hara, Rikuto Hirose, et al.
Cureus|November 25, 2025
Association Between Postoperative Complications and Real-Time Oxidative Stress Measurements Using Electron Spin Resonance: An Observational StudyShigekiyo Matsumoto, Yoshihide Kuribayashi, Takenori Makino, et al.
Plos One|December 31, 2020
Intense light as anticoagulant therapy in humansYoshimasa Oyama, Sydney Shuff, Pavel Davizon-Castillo, et al.
Current Pharmaceutical Design|September 25, 2018
The Circadian PER2 Enhancer Nobiletin Reverses the Deleterious Effects of Midazolam in Myocardial Ischemia and Reperfusion InjuryYoshimasa Oyama, Colleen Marie Bartman, Jennifer Gile, et al.
Pageof 5